AstraZeneca Plc will possibly conduct another global trial to evaluate the effectiveness of its coronavirus vaccine as the drugmaker attempts to clear up discouragement and confusion surrounding favorable results in its current study, CEO Pascal Soriot told Bloomberg.

Per Bloomberg’s report, AstraZeneca (AZN) wishes to test the coronavirus vaccine effectiveness rate after the company and its partner, the University of Oxford, acknowledged that a lesser dosage of vaccine is more efficient, which was accidentally noticed during the existing Phase 3 clinical trial.

Astra and Oxford reported on Monday that a lesser starting dose, followed by a full dose of the vaccine, produced a 90% efficacy rate as compared to 62% efficiency for two full-doses.

On Nov. 23, Merrill Lynch analyst Sachin Jain maintained a Buy rating on the stock with a price target of $69 (31.2% upside potential). The analyst is convinced that the interim coronavirus vaccine data lack details.